title: Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.
abstract: We sought to describe the clinical features and outcomes of therapy-related chronic myelomonocytic leukemia (t-CMML) and compare with those of de novo CMML. We identified 358 CMML patients, of whom 39 (11%) had t-CMML. Although the groups had similar demographic, hematologic, and molecular alteration profiles, the proportion of patients with intermediate or high CMML-specific cytogenetic risk in the t-CMML was significantly higher than that in the de novo CMML (P = .011). The median latency to develop t-CMML was 6 years. The median overall and leukemia-free survival duration of the t-CMML were shorter than those of the de novo CMML; however, t-CMML itself was not prognostic after adjusting for the effects of other covariates including cytogenetics. These results suggest that compared with de novo CMML, t-CMML is associated with more high-risk cytogenetics that manifest as poor outcomes. We propose that t-CMML be recognized as one of the therapy-related myeloid neoplasms.
authors.affiliation: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;
authors.forename: Koichi
authors.initials: K
authors.lastname: Takahashi
authors.forename: Naveen
authors.initials: N
authors.lastname: Pemmaraju
authors.forename: Paolo
authors.initials: P
authors.lastname: Strati
authors.forename: Graciela
authors.initials: G
authors.lastname: Nogueras-Gonzalez
authors.forename: Jing
authors.initials: J
authors.lastname: Ning
authors.forename: Carlos
authors.initials: C
authors.lastname: Bueso-Ramos
authors.forename: Rajyalakshmi
authors.initials: R
authors.lastname: Luthra
authors.forename: Sherry
authors.initials: S
authors.lastname: Pierce
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003582:Cytogenetics; D005260:Female; D006801:Humans; D015477:Leukemia, Myelomonocytic, Chronic / Q000139:chemically induced / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy; D009381:Neoplasms, Radiation-Induced / Q000175:diagnosis*; D011379:Prognosis; D011878:Radiotherapy / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents
references.citation: J Med. 1991;22(3):157-61
references.pmid: 1770323
references.citation: Blood. 2002 Feb 1;99(3):840-9
references.pmid: 11806985
references.citation: Blood. 2013 Apr 11;121(15):3005-15
references.pmid: 23372164
references.citation: J Clin Oncol. 2012 Jul 1;30(19):2340-7
references.pmid: 22585703
references.citation: Haematologica. 2011 Mar;96(3):375-83
references.pmid: 21109693
references.citation: Haematologica. 2005 May;90(5):691-3
references.pmid: 15921387
references.citation: Int J Hematol. 2009 Jun;89(5):699-703
references.pmid: 19430863
references.citation: Leuk Res. 2010 Jun;34(6):752-6
references.pmid: 19878996
references.citation: Leuk Res. 2013 May;37(5):552-5
references.pmid: 23391517
references.citation: J Clin Pharm Ther. 2006 Aug;31(4):401-6
references.pmid: 16882113
references.citation: Mod Pathol. 2009 Aug;22(8):1023-31
references.pmid: 19430420
references.citation: Am J Hematol. 2007 Mar;82(3):248-9
references.pmid: 16924641
references.citation: Br J Haematol. 1994 Aug;87(4):746-54
references.pmid: 7986717